DURECT CORP
DelistedCIK 1082038fmd_0PDG1TK0QHY8SSV43384E0YVDBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2025, 62 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 19 | 14 | 49 | 15 | 25 | 30 | 14 | 19 | 3 | 2 |
| Cost of revenue | 4 | 5 | 7 | 2 | 1 | 1 | 2 | 2 | 0 | 0 |
| Gross profit | 15 | 9 | 43 | 14 | 24 | 29 | 12 | 18 | 2 | 2 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 24 | 29 | 32 | 25 | 30 | 28 | 32 | 37 | 29 | 10 |
| Selling, general and administrative | 12 | 12 | 13 | 12 | 14 | 14 | 14 | 16 | 13 | 10 |
| Operating income | (21) | (32) | (2) | (24) | (20) | (13) | (34) | (35) | (40) | (19) |
| Interest expense | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | (2) | (1) | (2) | (1) | (2) | (2) | (0) | 12 | 0 |
| Income tax expense | 0 | 0 | (0) | – | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (25) | (21) | (14) | (36) | (35) | (28) | (18) |
| Net income | (23) | (35) | (4) | (25) | (21) | (1) | (36) | (35) | (28) | (8) |
| Net income to common shareholders | – | – | – | – | – | – | (36) | (35) | (32) | (8) |